This is the authors' abstract. We don't add key points for this paper.
The price of potential long-term survival to metastatic tumors is an atypical immune toxicity, reflecting the mechanism of action of anti-CTLA-4 antibodies. A better knowledge of these irAEs and its management in a multidisciplinary approach will help to reduce morbidity and therapy interruptions.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bertrand et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: